drugset / Trial / NCT06665217
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-ZLP as induction therapy in patients with DLBCL.
Timeline
- Start
- 2025-09-24
- Primary completion
- 2029-01
- Completion
- 2030-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glofitamab | Monoclonal antibody | 30 mg | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Subject | Polatuzumab Vedotin | Other / unclassified | 1.8 mg/kg | Intravenous |
| Subject | Prednisone | Other / unclassified | 60 mg/m2 | Oral |
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |